Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMoonLake Immunotherapeutics

MoonLake Immunotherapeutics

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
13.51 USD 0.95 ( 7.56%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1927712
Market Cap
1028.09M

Momentum Score

…

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.51
Low
13.90
High
52 Week Price Range
5.95
Low
62.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
12.56
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.25
ROE
-67.48%
Net Debt
-258.81M
ROCE
-58.70%
Diluted EPS TTM
-3.84

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -229.71M -120.96M -43.98M -64.47M -4.54M
Minority interest 3.00M 2.31M 6.98M -14.53M -
Net income -227.32M -118.94M -36.01M -64.51M -4.54M
Selling general administrative 41.97M 30.32M 22.32M 23.01M 4.57M
Selling and marketing expenses - 30289.46M 22298.89M - 18.03M
Gross profit -2.62M -1.38M -0.01M -0.01M -0.00M
Reconciled depreciation 2.62M 1.38M 0.01M 0.01M -
Ebit -222.46M -120.96M -54.12M -65.06M -4.57M
Ebitda -219.85M -119.58M -54.11M -65.05M -4.57M
Depreciation and amortization 2.62M 1.38M 0.01M 0.01M 0.00M
Non operating income net other - - - 0.59M 0.03M
Operating income -244.83M -143.09M -54.12M -65.06M -4.57M
Other operating expenses 244.83M 143.09M 54.12M 65.06M 4.57M
Interest expense 7.25M 0.00M - 0.59M 0.00M
Tax provision 0.61M 0.28M 0.06M 0.04M -
Net interest income -7.25M 0.00M - - -
Income tax expense 0.61M 0.28M 0.09M 0.04M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 242.22M 143.09M 54.11M 65.06M 4.57M
Cost of revenue 2.62M 1.38M 0.01M 0.01M 0.00M
Total other income expense net 15.12M 22.13M 10.14M 0.59M 0.03M
Net income from continuing ops -230.32M -121.24M -52.66M -50.10M -4.54M
Net income applicable to common shares - - - -49.97M -4.54M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 424.43M 477.93M 526.54M 76.84M 9.68M
Other current assets 22.86M 23.42M 2.10M 4.18M 0.13M
Total liab 119.95M 24.54M 13.05M 8.08M 21.33M
Total stockholder equity 304.48M 446.82M 495.68M 48.90M -11.65M
Deferred long term liab - - - - 4.03M
Other current liab 44.24M 11.77M 8.40M 7.26M 4.66M
Common stock 0.01M 0.01M 0.01M 0.01M 0.04M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.11M
Retained earnings -462.91M -235.59M -116.66M -80.65M -53.64M
Other liab - - - - 0.24M
Other assets - -473814.56M 0.00M - -
Cash 334.52M 180.43M 451.17M 39.51M 8.04M
Total current liabilities 45.48M 22.46M 9.97M 7.67M 21.09M
Current deferred revenue - - -0.19M - -
Net debt -258.81M -177.60M -447.47M -39.22M 6.96M
Short term debt 1.23M 1.37M 1.20M 0.15M 15.00M
Short long term debt - - - - 15.00M
Short long term debt total 75.71M 2.83M 3.70M 0.28M 15.00M
Other stockholder equity 766.78M 677.41M 609.97M 129.19M 42.06M
Property plant equipment - - - 0.05M 0.05M
Total current assets 421.69M 474.29M 514.17M 76.51M 9.64M
Net tangible assets - - - 48.90M 107.94M
Short term investments 59.45M 267.60M 59.84M 32.61M -
Net receivables 4.87M 2.84M 1.06M 0.22M 0.15M
Long term debt 74.10M - - - -
Inventory - - - - 1.32M
Accounts payable 28.43M 8.68M 0.55M 0.25M 1.43M
Noncontrolling interest in consolidated entity - - - 19.87M -
Accumulated other comprehensive income 0.60M 5.00M 2.36M 0.35M -0.17M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -80.65M -7.06M
Non currrent assets other 0.60M -267333.30M 8.42M 0.28M -115.04M
Non current assets total 2.74M 3.64M 12.37M 0.33M 0.05M
Capital lease obligations 1.61M 2.83M 3.81M 0.28M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 203.03M -205.60M -132.15M -32.32M -
Change to liabilities - - - 1.37M 3.80M
Total cashflows from investing activities 202.99M -205.60M - -32.34M -0.06M
Net borrowings 73.02M 0.00M - -15.00M -0.06M
Total cash from financing activities 146.00M 51.31M 479.70M 119.69M 43.26M
Change to operating activities - - - - 3.68M
Net income -229.10M -121.24M -36.01M -64.51M -53.64M
Change in cash 154.09M -270.74M 411.66M 31.47M 6.70M
Begin period cash flow 180.43M 451.17M 39.51M 8.04M 1.34M
End period cash flow 334.52M 180.43M 451.17M 39.51M 8.04M
Total cash from operating activities -196.01M -116.59M -42.78M -55.89M -35.18M
Issuance of capital stock 72.39M 52.54M 451.29M 451.29M -
Depreciation 2.62M 1.38M 0.01M 0.01M 0.00M
Other cashflows from investing activities - -145057.79M - - -
Dividends paid - - - - 0.05M
Change to account receivables -2.02M -1.79M -0.84M -0.07M -0.15M
Sale purchase of stock - -0.00M - 0.00M -0.01M
Other cashflows from financing activities 146.00M -1.23M -2.75M 134.69M 0.05M
Change to netincome - - - 9.72M -4.54M
Capital expenditures 0.04M 0.52M 0.28M 0.02M 0.05M
Change receivables - - - -0.07M -
Cash flows other operating - - - -2.43M 0.13M
Cash and cash equivalents changes - - - 31.46M -0.67M
Change in working capital 19.88M -3.78M -6.22M -1.43M 4.48M
Stock based compensation 12.90M 7.28M 7.11M 9.65M 0.01M
Other non cash items -2.30M -0.23M 0.30M 0.37M 12.57M
Free cash flow -196.04M -117.11M -43.06M -55.91M -35.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MLTX
MoonLake Immunotherapeutics		 0.95
7.56%		 13.51 - - - 2.42 -41.53
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Dorfstrasse 29, Zug, Switzerland, 6300

41 415108022

https://www.moonlaketx.com

130

Name Title Year Born
Dr. Jorge Santos da Silva Co-Founder, CEO & Director 1978
Dr. Kristian Reich Co-Founder & Chief Scientific Officer 1966
Mr. Matthias Bodenstedt Chief Financial Officer 1988
Mr. Oliver Daltrop Chief Technical Officer NA
Ms. Nuala Brennan Chief Clinical Devel. Officer NA
Nicolas Mosimann General Counsel NA
Luciana Marques Director of HR, People & Culture NA
Ms. Nuala Brennan Chief Clinical Development Officer NA
Dr. Jorge Santos da Silva Ph.D. Co-Founder, Interim Chair of the Board & CEO 1977
Dr. Kristian Reich M.D., Ph.D. Co-Founder & Chief Scientific Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -2.89%

  • Communication Services

    +0.25%

  • Consumer Cyclical

    +0.37%

  • Consumer Defensive

    -0.02%

  • Energy

    -0.30%

  • Financial Services

    -1.06%

  • Healthcare

    -0.73%

  • Industrials

    -0.49%

  • Real Estate

    +0.22%

  • Technology

    -1.52%

  • Utilities

    +0.08%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…